Teachers Retirement System of The State of Kentucky Has $1.89 Million Stake in Illumina, Inc. (NASDAQ:ILMN)

Teachers Retirement System of The State of Kentucky trimmed its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,587 shares of the life sciences company’s stock after selling 562 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Illumina were worth $1,891,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Kestra Advisory Services LLC lifted its holdings in shares of Illumina by 2.9% in the third quarter. Kestra Advisory Services LLC now owns 8,878 shares of the life sciences company’s stock worth $1,219,000 after acquiring an additional 252 shares during the last quarter. QRG Capital Management Inc. bought a new position in shares of Illumina in the third quarter worth about $462,000. Envestnet Portfolio Solutions Inc. bought a new position in shares of Illumina in the third quarter worth about $407,000. Aigen Investment Management LP bought a new position in shares of Illumina in the third quarter worth about $226,000. Finally, Rathbones Group PLC lifted its holdings in shares of Illumina by 45.7% in the third quarter. Rathbones Group PLC now owns 4,349 shares of the life sciences company’s stock worth $597,000 after acquiring an additional 1,365 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on ILMN shares. Robert W. Baird increased their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $253.00 price objective on shares of Illumina in a report on Tuesday, April 9th. Stephens reiterated an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Tuesday, May 7th. Evercore ISI dropped their price objective on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Finally, StockNews.com initiated coverage on shares of Illumina in a report on Saturday. They issued a “buy” rating for the company. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $158.14.

Illumina Stock Up 0.3 %

ILMN stock opened at $108.57 on Friday. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $202.85. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $17.30 billion, a PE ratio of -13.32 and a beta of 1.20. The stock has a 50-day simple moving average of $112.71 and a two-hundred day simple moving average of $127.51.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm earned $0.08 earnings per share. Illumina’s revenue was down 1.0% on a year-over-year basis. On average, equities analysts predict that Illumina, Inc. will post 1.04 EPS for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.